Merck Reports Ten-Year KEYNOTE-006 Data for Keytruda in Advanced Melanoma

Merck today presented ten-year overall survival data from the Phase 3 KEYNOTE-006 trial evaluating Keytruda (pembrolizumab) versus ipilimumab in patients with advanced melanoma. The data showed that 34% of patients in the Keytruda arm were alive at ten years compared to 23% in the ipilimumab arm. These unprecedented long-term survival data demonstrate the transformative impact of Keytruda in advanced melanoma.